Overall rank by patents
#28,667
Across all tracked assignees
USPTO PatentsView assignee record - 9 granted patents across 7 technology areas, active 2022–2023. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61Q (SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS).
The verdict
Exocobio holds 9 US patents across 7 technology areas, rank #28,667 of 50,000 tracked assignees.
Exocobio Inc. has been granted 9 US utility patents between 2022 and 2023, placing Exocobio Inc. at rank #28,667 across all assignees tracked by PlainPatent. This portfolio spans 7 distinct Cooperative Patent Classification (CPC) subclasses, averaging 19.1 claims per patent with primary concentration in A61Q (SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS). As a Foreign Corporation, Exocobio Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Exocobio sits between Exicure, Inc. (9 patents, rank #28,663) and Eagantu Ltd. (9 patents, rank #28,671) - the closest US assignees by grant volume. The composite Innovation Score of 48.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2022 through 2023, with 9 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Exocobio Inc.'s 19.1 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 7 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Exocobio Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
EXICURE, INC.
9 patents
EXILANT Technologies Private Limited
9 patents
EXPLISEAT
9 patents
EXTERRAN WATER SOLUTIONS ULC
9 patents
EYESENSE GMBH
9 patents
EYL INC.
9 patents
EZ-PRO TEXTURE INC.
9 patents
Eagantu Ltd.
9 patents
EXoCoBio Inc.
9 patents
What this shows Exocobio holds 9 patents at rank #28,667, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #28,667 in granted patent volume.
Other assignees with the most granted patents in Exocobio's primary technology class.
Exocobio's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
49 Top 16% higher than 84% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2022 | 5 | 55.6% |
| 2023 | 4 | 44.4% |
Top 7 of 7 technology areas
Overall rank by patents
#28,667
Across all tracked assignees
48.8 out of 100
How to use this portfolio
Exocobio's 9 grants land it in the top 16% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.